癌症干细胞的分子影像及其在治疗耐药中的作用
本综述探讨PET和SPECT等分子影像技术用于无创检测癌症干细胞(CSC),实时监测CSC以预测治疗耐药并指导个体化治疗;文中涵盖CSC生物学特征、耐药机制、CSC特异性生物标志物的识别与靶向,以及CSC影像临床转化的挑战与机遇。
要点
- 癌症干细胞(CSC)是导致治疗耐药和复发的重要驱动因素。
- PET和SPECT等分子影像技术有望实现CSC的无创检测与实时监测。
- CSC影像有望预测治疗耐药并指导个体化治疗策略。
核心结论
- 分子影像技术如PET和SPECT可实现癌症干细胞的无创检测,实时监测CSC有望预测治疗耐药并指导个体化治疗。
研究设计与样本
- 本综述探讨PET和SPECT等分子影像技术在癌症干细胞无创检测中的应用。
主要发现
- CSC是具有自我更新能力的细胞亚群,是难治性疾病的关键驱动因素。
- 分子影像技术可提供CSC的实时监测,有望预测治疗耐药并指导个体化治疗。
- 综述涵盖CSC生物学特征、耐药机制及CSC特异性生物标志物的识别与靶向。
- 综述讨论了CSC影像临床转化的挑战与机遇及改善患者结局的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite recent therapeutic breakthroughs, cancer patients continue to face high recurrence and mortality rates due to treatment resistance. Cancer stem cells (CSCs), a subpopulation with self-renewal capabilities, are key drivers of refractive disease. This review explores the application of molecular imaging techniques, such as PET and SPECT, for the noninvasive detection of CSCs. By providing real-time monitoring of CSCs, these imaging methods have the potential to predict therapy resistance and guide personalized treatment approaches. Here, we cover the biological characteristics of CSCs, mechanisms of therapy resistance, and the identification and targeting of CSC-specific biomarkers with molecular imaging. Additionally, we address the challenges and opportunities for the clinical translation of CSC imaging, highlighting strategies where CSC imaging can be used to improve patient outcomes.
引用
- Dos Santos SN, Witney TH. Molecular Imaging of Cancer Stem Cells and Their Role in Therapy Resistance. J Nucl Med. 2025. PMID: 39753364. doi:10.2967/jnumed.124.267657
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。